genglob magazine


magazine by for generics, medicines and alternative treatments like ayurveda and traditional chinese

No NHS Funding For Breast Cancer Drug Lapatinib

Lapatinib Breast Cancer

UK’s drug watchdog National Institute for Clinical Excellence (NICE) has advised against public funding of Tyverb® (lapatinib) on grounds of cost. The drug is a treatment for an aggressive form of advanced breast cancer (ErbB2-positive). Drug makers GSK say they are considering an appeal against the decision. Read the rest of this entry »